Clinical trials for cancer in San Antonio

The Methodist Healthcare Cancer Network is one of the leading cancer research programs in Texas and has provided advancements in cancer treatments. We bring the latest cancer treatments to San Antonio by participating in cancer care research trials and studies. Clinical trials provide patients with either the best treatment currently available or a new and possibly more effective therapy.

For more information about our cancer clinical trials, please call askSARAH at (210) 507-0941.

How do clinical trials work?

Studies are broken down into different phases that each focus on certain things.

  • Phase 1 investigates safety, side effects and the best dose of study drugs.
  • Phase 2 determines the effectiveness and safety.
  • Phase 3 looks at effectiveness, side effects and safety compared with other treatments.
  • Phase 4 gathers more information after the Food and Drug Administration (FDA) approves the drug, and it is on the market.

Each cancer trial has a written detailed study design called a protocol. A protocol includes why the trial is needed, the purpose of the trial, what drug or drugs are being tested and who can join the study. It also includes:

  • Safety measures
  • How outcomes will be measured
  • What information will be gathered about you

Standard treatment

Standard treatment is a treatment that experts agree is appropriate, accepted and widely used. As with any treatment, it will have side effects. For example, the standard treatment for some blood cancers may only be somewhat effective, in these instances, you may want to consider a clinical trial.


Randomization enables doctors to compare new treatments with standard treatments. Patients are divided into different groups at random. The control group receives the best standard treatment available and the treatment group receives the treatment under study. Sometimes a placebo may be used, but rarely in cancer studies.


A placebo is designed to look like the medicine being tested, but it is not active. A study may compare standard treatment plus a new treatment to standard treatment plus a placebo. You will be told if the study uses a placebo, but you will not know if you are getting the placebo, nor will your study team—this is called “blinding,” which allows the research team to look at your side effects without bias.

Types of clinical trials we offer

Your eligibility depends on several criteria, including your age and sex, your cancer type and stage of the cancer, previous treatments, and your overall medical history. If you’re interested in participating in a clinical trial, view the list of open San Antonio trials below and talk to your doctor to determine which one may be right for you:

Acute Myeloid Leukemia (AML)

  • SCRI AML 49: A Phase 3b, single arm, multicenter open label study of Ventoclax in Combination with Azacitidine or Decitabine in an Outpatient setting in AML patients ineligible for Intensive Chemotherapy Abbvie M19-072
  • SCRI AML 48: A Phase II study assessing CPX-351 (Vyxeos) with Quizartinib for the treatment of relapsed or refractory FLT3-ITD Mutation Positive AML

Acute Myeloid Leukemia (AML)

  • BMT 41 Abb Vie: A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML)
  • PBMTC ONC 1701 (EndRAD): A phase II pilot trial to estimate survival after a non-TBI based conditioning regimen in patients diagnosed with B-ccule lymphoblastic leukemia who are pre-allogeneic hematopoietic cell transplantation next generation sequence minimal residual disease negative


  • SCRI BMT 24: A Phase 2 Single Arm Study of Nivolumab as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkins lymphoma at risk of relapse or progression.


  • PBMTC SUP 1601: Pathogen Identification in Pediatric Hematopoietic Stem Cell Transplant Patients with Suspected Lower Respiratory Tract Infection


  • SCRI BMT 35 Equillium: A Phase 1B/2 study to evaluate the safety, tolerability, Pharacokinetics, phyarmacodynamics and clinical activity of EQ001 in subjects with newly diagnosed acute graft versus host disease
  • SCRI BMT 29 Incyte: A Pilot Study of INCB039110 (Itacitinib) for the treatment of Steroid Refractory Chronic Graft Versus Host Disease


  • SCRI BMT 18: A Multi-center Randomized Phase 2 study of the Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-Cell Lymphoma (DLBCL).
  • CTN 1502: Cord Blood and Haploidentical Aplastic Anemia Transplantation (CHAMP)
  • CSIDE: NMD 1801 entitled, “A randomized trial of low versus moderate exposure busulfan for infants with severe combined immunodeficiency (SCID) receiving TCRαβ+/CD19+ depleted transplantation
  • BMT CTN 1704: Composite Health Assessment Model for Older Adults: Applying Pre-transplant Comorbidity, Geriatric Assessment, and Biomarkers to Predict Non-Relapse Mortality after Allogeneic Transplantation (CHARM) study
  • STAR- HLA Matched Related Hematopoietic Stem Cell Transplantation for Children with Less Severe Sickle Cell Disease: a Sickle Transplant Alliance for Research (STAR) Trial
  • Vanderbilt: BMT 12108: A Non-Myeloablative Conditioning and Transplantation of partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients with Sickle Cell Disease and Other Hemoglobinopathies
  • BMT CTN 1507: Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease


  • SCRI LYM 146 Juno: A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting
  • SCRI LYM 147 Novartis: Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial
  • Novartis Expanded Access: Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or large B-Cell lymphoma patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification of commercial release

Multiple Myeloma

  • SCRI MM 100 Juno: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects with Relapsed or Refractory Multiple Myeloma


  • Novartis: A phase II trial of Tisagenlecleucel in first line high risk pediatric and young adult patients with B cell acute lymphoblastic leukemia wo are minimal residual disease positive at the end of consolidation therapy
  • ALL 06 Autolus: An open label, multi-centre, phase Ib/II study evaluating the safety and efficacy of Auto1, a CAR T cell treatment targeting CD19, in adult patients with relapsed or refractory B cell Acute Lymphoblastic Leukemia

Sickle Cell Disease

  • CTX001-121 SCD Trial: A Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Severe Sickle Cell Disease


  • CTX001-121 SCD Trial: A Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Severe Sickle Cell Disease

About Sarah Cannon Cancer Institute

Methodist Healthcare is part of Sarah Cannon, the Cancer Institute of HCA Healthcare. Our family of hospitals provides comprehensive cancer services with convenient access to cutting-edge therapies for people facing cancer in our communities. From diagnosis, to treatment and survivorship care, our oncology expertise ensures you have access to locally-trusted care with the support of a globally-recognized network.

askSARAH helpline

Have cancer questions? We can help. askSARAH is a dedicated helpline for your cancer-related questions. Our specially-trained nurses are available 24/7 and all calls are confidential. Contact askSARAH at (210) 507-0941 or chat online at askSARAH.